Persson, Emma
Gregersson, Pernilla
Gustafsson, Anna
Fitzpatrick, Paul
Rhost, Sara
Ståhlberg, Anders
Landberg, Göran http://orcid.org/0000-0001-9004-9403
Funding for this research was provided by:
Knut och Alice Wallenbergs Stiftelse
Wallenberg Center for Molecular and Translational Medicine
Cancerfonden (19-0306, 20-0306 PjF 2016-438, 2016-486)
Vetenskapsrådet (2017-01392, 2016-01530)
ALF agreement (716321, 72109)
Stiftelserna Wilhelm och Martina Lundgrens
Stiftelsen Assar Gabrielssons Fond
VINNOVA
BioCare National Strategic Research Program
University of Gothenburg
Article History
Received: 9 November 2020
Accepted: 27 April 2021
First Online: 5 June 2021
Declarations
:
: Informed consent was waived and processing of patient material and information was approved by the Regional Research Ethics Committee in Gothenburg (DNR: 515-12 and T972-18).
: Not applicable.
: There are two conflicts of interest associated with this manuscript. Ståhlberg is a shareholder in TATAA Biocenter and Landberg and Ståhlberg are board members of iScaff Pharma AB.